Soleil Securities Reiterates a 'Buy' on Pfizer (PFE); Recent Pullback Provides Opportunity Ahead of Catalysts
PFE Hot Sheet
Rating Summary:13 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 3 | Down: 1 | New: 5
Soleil Securities reiterates a 'Buy' on Pfizer (NYSE: PFE), price target $20.
Soleil analyst says, "PFE is down approximately 8% since releasing solid Q3'09 results on Tuesday, October 20 (vs. S&P 500 down 5% and AMEX Drug Index down 3.5%), despite no change in fundamentals. We believe this transient weakness affords long-term investors an attractive entry point into the stock...We have updated our model to reflect the current run rates, prescription trends, guidance, and Wyeth products. Our 2009 EPS is $2.06, and our 2010 EPS projection is $2.24, implying 9% growth. With Q3' results and the close of the WYE acquisition behind us, we believe that the next significant catalysts will be a December decision on the dividend (currently at $0.64, consensus at $0.70 - $0.72 for 2010) and 2010 guidance to be issued in January...We continue to believe that the integration will proceed ahead of the stated goal of $4 billion in synergies, and that 2010 will see the benefit of improved operating efficiencies at the combined company."
To see more analyst ratings on PFE Click Here.
Pfizer Inc. engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide.
Soleil analyst says, "PFE is down approximately 8% since releasing solid Q3'09 results on Tuesday, October 20 (vs. S&P 500 down 5% and AMEX Drug Index down 3.5%), despite no change in fundamentals. We believe this transient weakness affords long-term investors an attractive entry point into the stock...We have updated our model to reflect the current run rates, prescription trends, guidance, and Wyeth products. Our 2009 EPS is $2.06, and our 2010 EPS projection is $2.24, implying 9% growth. With Q3' results and the close of the WYE acquisition behind us, we believe that the next significant catalysts will be a December decision on the dividend (currently at $0.64, consensus at $0.70 - $0.72 for 2010) and 2010 guidance to be issued in January...We continue to believe that the integration will proceed ahead of the stated goal of $4 billion in synergies, and that 2010 will see the benefit of improved operating efficiencies at the combined company."
To see more analyst ratings on PFE Click Here.
Pfizer Inc. engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide.
You May Also Be Interested In
- Pfizer (PFE) Promotes Olivier Brandicourt to GM of Emerging Markets, Established Products Units
- UBS Raises Price Target and Estimates on Williams-Sonoma (WSM); Positive Momentum Is Beginning To Pick Up
- Nomura Securities Sees Trends Continuing To Be Difficult at Wet Seal, Inc. (WTSLA); Cutting FY12/13 Estimates
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Soleil Securities, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
